Syngene International Limited — Updates, 19-03-2025: Press Release

Syngene International Limited has concluded the acquisition of its first biologics manufacturing facility in the USA from Emergent BioSolutions Inc., valued at USD 36.5 million. This state-of-the-art facility features multiple monoclonal antibody manufacturing lines and will increase Syngene's total single-use bioreactor capacity to 50,000L. The acquisition is expected to enhance service continuity for customers, who will benefit from Syngene’s integrated offerings, including cell line development, process optimization, and both clinical and commercial supply. With this strategic move, Syngene aims to bolster its global manufacturing capabilities and strengthen its market position in the biopharmaceutical sector. Watch closely as this development may provide significant growth opportunities for the company.